Boehringer Ingelheim International GmbH
Boehringer Ingelheim International GmbH, a leading global pharmaceutical company, is headquartered in Ingelheim am Rhein, Germany. Founded in 1885, the company has established a strong presence in the healthcare industry, focusing on human pharmaceuticals, animal health, and biopharmaceutical contract manufacturing. With a commitment to innovation, Boehringer Ingelheim is renowned for its core products, including prescription medications for respiratory diseases, cardiovascular conditions, and diabetes management. The company’s unique approach to research and development has positioned it as a key player in the market, consistently delivering groundbreaking therapies. Notable achievements include significant advancements in veterinary medicine and a robust pipeline of new treatments, reinforcing its status as one of the top pharmaceutical firms globally. Boehringer Ingelheim continues to prioritise improving patient outcomes and animal health through its dedicated efforts in scientific excellence.
DitchCarbon Score
How does Boehringer Ingelheim International GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Boehringer Ingelheim International GmbH's score of 20 is lower than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Boehringer Ingelheim International GmbH's reported carbon emissions
Boehringer Ingelheim International GmbH, headquartered in Germany (DE), currently does not have specific carbon emissions data available for the most recent year. As a current subsidiary, it inherits its climate commitments and emissions data from its parent organization, which is not specified in the provided information. The company has not outlined any specific reduction targets or initiatives, nor does it appear to have made any formal climate pledges. This lack of publicly available data suggests that Boehringer Ingelheim may still be in the process of developing its climate strategy or reporting framework. As part of the pharmaceutical industry, Boehringer Ingelheim is expected to align with broader sustainability goals, including potential commitments to the Science Based Targets initiative (SBTi) and other industry standards. However, without specific data or targets, it is difficult to assess their current climate impact or future commitments.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Boehringer Ingelheim International GmbH is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
